<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="9" family="LGOLEL+Arial,Italic" color="#000000"/>
	<fontspec id="1" size="9" family="LGOKNL+Arial" color="#000000"/>
	<fontspec id="2" size="9" family="LGOLNA+Arial,Bold" color="#000000"/>
	<fontspec id="3" size="7" family="LGOLEL+Arial,Italic" color="#000000"/>
	<fontspec id="4" size="11" family="LGOLHN+GillSans" color="#000000"/>
	<fontspec id="5" size="10" family="LGOLIN+Giovanni-Book" color="#000000"/>
	<fontspec id="6" size="9" family="LGOLPA+GillSans" color="#000000"/>
	<fontspec id="7" size="8" family="LGOLHN+GillSans" color="#000000"/>
	<fontspec id="8" size="8" family="LGOLPA+GillSans" color="#000000"/>
	<fontspec id="9" size="8" family="LGOLJO+GillSans" color="#000000"/>
<text top="41" left="55" width="106" height="10" font="0"><i>BMC Emergency Medicine</i></text>
<text top="41" left="162" width="27" height="10" font="1"> 2007, </text>
<text top="41" left="189" width="5" height="10" font="2"><b>7</b></text>
<text top="41" left="194" width="13" height="10" font="1">:14</text>
<text top="41" left="367" width="187" height="10" font="1">http://www.biomedcentral.com/1471-227X/7/14</text>
<text top="756" left="508" width="46" height="10" font="1">Page 2 of 9</text>
<text top="769" left="432" width="122" height="8" font="3"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="60" height="10" font="4"><b>Background</b></text>
<text top="98" left="55" width="241" height="9" font="5">Sustained hyperglycemia is a known risk factor for adverse</text>
<text top="110" left="55" width="241" height="9" font="5">outcomes in the critically ill patient, whether or not the</text>
<text top="122" left="55" width="241" height="9" font="5">patient has a history of diabetes mellit<a href="">us [1-3</a>]. There are</text>
<text top="134" left="55" width="241" height="9" font="5">many factors that affect glycemic control; metabolic</text>
<text top="145" left="55" width="241" height="9" font="5">derangement and counter-regulation, increased stress,</text>
<text top="157" left="55" width="241" height="9" font="5">decrease insulin (resistance or underproduction),</text>
<text top="169" left="55" width="241" height="9" font="5">increased glucose administration just to name a few [<a href="">4,5].</a></text>
<text top="181" left="55" width="241" height="9" font="5">Although short term glycemic increases related to stress</text>
<text top="192" left="55" width="241" height="9" font="5">are not associated with rise in mortality in all populations</text>
<text top="204" left="55" width="31" height="9" font="5"><a href="">[1,6,7].</a></text>
<text top="228" left="55" width="241" height="9" font="5">Intensive insulin therapy is emerging as a treatment</text>
<text top="239" left="55" width="241" height="9" font="5">modality. At the time of our study, other than cardiovas-</text>
<text top="251" left="55" width="241" height="9" font="5">cular surgery patients [<a href="">1,8,9], it w</a>as uncertain what spe-</text>
<text top="263" left="55" width="241" height="9" font="5">cific patient populations benefit from intensive insulin</text>
<text top="275" left="55" width="241" height="9" font="5">therapy. Other populations are beginning to emerge in</text>
<text top="286" left="55" width="241" height="9" font="5">the literature <a href="">[7]; trauma pat</a>i<a href="">ents [10,11], intrao</a>perative</text>
<text top="298" left="55" width="147" height="9" font="5"><a href="">[12], and</a> medical patients [<a href="">13</a>,<a href="">14].</a></text>
<text top="322" left="55" width="241" height="9" font="5">Despite some uncertainties, the management of hypergly-</text>
<text top="333" left="55" width="241" height="9" font="5">cemia utilizing insulin protocols is fast becoming a new</text>
<text top="345" left="55" width="241" height="9" font="5">standard in critical care pr<a href="">actice [1,13-23</a>]. Nurse initiated</text>
<text top="357" left="55" width="241" height="9" font="5">protocols generally have been found to improve patient</text>
<text top="369" left="55" width="241" height="9" font="5">ca<a href="">re [13</a>,<a href="">17,22], limit</a> the prescribing variability</text>
<text top="380" left="55" width="241" height="9" font="5"><a href="">[15,16,18</a>,<a href="">20,24]</a> and contribute to financial cost savings</text>
<text top="392" left="55" width="241" height="9" font="5"><a href="">[17]. Howe</a>ver it is unknown if a nurse initiated IIP is</text>
<text top="404" left="55" width="241" height="9" font="5">effective and safe across different ICU populations. Also,</text>
<text top="416" left="55" width="241" height="9" font="5">it appears similar protocols in different populations'</text>
<text top="427" left="55" width="241" height="9" font="5">yields different clinical outcomes <a href="">[9,14]</a>. It is unclear if the</text>
<text top="439" left="55" width="241" height="9" font="5">protocol or operation of the protocol leads in part to these</text>
<text top="451" left="55" width="48" height="9" font="5">differences.</text>
<text top="87" left="313" width="241" height="9" font="5">In this study we sought to determine if the IIP was effec-</text>
<text top="98" left="313" width="241" height="9" font="5">tive and safe in bringing blood glucose values within the</text>
<text top="110" left="313" width="241" height="9" font="5">target range of 100–150 mg/dL among the three different</text>
<text top="122" left="313" width="241" height="9" font="5">ICUs (surgical, medical and coronary care). We were also</text>
<text top="134" left="313" width="241" height="9" font="5">interested in glycemic control across different ICU popu-</text>
<text top="145" left="313" width="241" height="9" font="5">lations in the first 48 hours after the IIP was discontinued,</text>
<text top="157" left="313" width="185" height="9" font="5">when the patients transition out of the ICU.</text>
<text top="181" left="313" width="43" height="10" font="4"><b>Methods</b></text>
<text top="193" left="313" width="28" height="9" font="6"><i><b>Design</b></i></text>
<text top="204" left="313" width="241" height="9" font="5">We conducted a descriptive retrospective review of 366</text>
<text top="216" left="313" width="241" height="9" font="5">patients having 28,192 blood glucose values in the analy-</text>
<text top="228" left="313" width="241" height="9" font="5">sis of outcomes after Mayo Foundation Institutional</text>
<text top="239" left="313" width="241" height="9" font="5">Review Board (IRB) approval was granted. Patients had</text>
<text top="251" left="313" width="241" height="9" font="5">been cared for in one of three ICUs in a quaternary care</text>
<text top="263" left="313" width="241" height="9" font="5">hospital at Mayo Clinic Rochester, MN where an intensive</text>
<text top="275" left="313" width="241" height="9" font="5">insulin protocol was utilized. The ICUs included a 24-bed</text>
<text top="286" left="313" width="241" height="9" font="5">Surgical Trauma Intensive Care Unit (STICU), a 24-bed</text>
<text top="298" left="313" width="241" height="9" font="5">Medical ICU (MICU), and a 16-bed Coronary Care Unit</text>
<text top="310" left="313" width="31" height="9" font="5">(CCU).</text>
<text top="334" left="313" width="34" height="9" font="6"><i><b>Patients</b></i></text>
<text top="345" left="313" width="241" height="9" font="5">Inclusion criteria included adult patients, 15 years of age</text>
<text top="357" left="313" width="241" height="9" font="5">and older, admitted to STICU, MICU or CCU who had a</text>
<text top="369" left="313" width="241" height="9" font="5">blood glucose level greater than 150 mg/dL while on the</text>
<text top="380" left="313" width="241" height="9" font="5">unit and were placed on an IIP during the identified data</text>
<text top="392" left="313" width="241" height="9" font="5">collection time frame October 2003-June 2004. 366 out</text>
<text top="404" left="313" width="241" height="9" font="5">of 386 eligible patients were used for data analysis. Eight-</text>
<text top="416" left="313" width="241" height="9" font="5">een patients were excluded since they did not grant</text>
<text top="427" left="313" width="241" height="9" font="5">approval for use of their data for research purposes. One</text>
<text top="439" left="313" width="241" height="9" font="5">patient was not started on insulin drip and one was on a</text>
<text top="451" left="313" width="241" height="9" font="5">modified insulin drip prior to ICU admission. There were</text>
<text top="463" left="313" width="241" height="9" font="5">not any other exclusion criteria. Patients readmitted to the</text>
<text top="474" left="313" width="241" height="9" font="5">ICU during the same or subsequent hospitalization were</text>
<text top="494" left="55" width="116" height="7" font="7"><b>Table 1: Patient characteristics</b></text>
<text top="512" left="173" width="63" height="7" font="7"><b>STICU (n = 162)</b></text>
<text top="512" left="275" width="60" height="7" font="7"><b>MICU (n = 110)</b></text>
<text top="512" left="379" width="51" height="7" font="7"><b>CCU (n = 94)</b></text>
<text top="512" left="490" width="7" height="7" font="8"><i><b>p </b></i></text>
<text top="512" left="497" width="22" height="7" font="7"><b>Value</b></text>
<text top="535" left="59" width="53" height="7" font="9">Age, mean (SD)</text>
<text top="535" left="187" width="36" height="7" font="9">59.9 (19.5)</text>
<text top="535" left="287" width="36" height="7" font="9">61.4 (17.6)</text>
<text top="535" left="386" width="36" height="7" font="9">67.8 (12.7)</text>
<text top="535" left="497" width="14" height="7" font="9">0.01</text>
<text top="545" left="59" width="74" height="7" font="9">Gender, Female, n (%)</text>
<text top="545" left="193" width="24" height="7" font="9">79 (49)</text>
<text top="545" left="292" width="24" height="7" font="9">57 (52)</text>
<text top="545" left="392" width="24" height="7" font="9">35 (37)</text>
<text top="545" left="497" width="14" height="7" font="9">0.09</text>
<text top="555" left="59" width="76" height="7" font="9">Weight, kg, mean (SD)</text>
<text top="555" left="187" width="36" height="7" font="9">90.5 (32.9)</text>
<text top="555" left="287" width="36" height="7" font="9">84.7 (25.8)</text>
<text top="555" left="386" width="36" height="7" font="9">87.4 (23.0)</text>
<text top="555" left="497" width="14" height="7" font="9">0.70</text>
<text top="565" left="59" width="76" height="7" font="9">Height, cm, mean (SD)</text>
<text top="565" left="187" width="36" height="7" font="9">169.0 (9.6)</text>
<text top="565" left="285" width="40" height="7" font="9">167.4 (19.4)</text>
<text top="565" left="384" width="40" height="7" font="9">170.5 (10.2)</text>
<text top="565" left="497" width="14" height="7" font="9">0.44</text>
<text top="576" left="59" width="51" height="7" font="9">Diabetes, n (%)</text>
<text top="576" left="193" width="24" height="7" font="9">48 (30)</text>
<text top="576" left="293" width="24" height="7" font="9">47 (43)</text>
<text top="576" left="392" width="24" height="7" font="9">57 (61)</text>
<text top="576" left="489" width="29" height="7" font="9">&lt; 0.0001</text>
<text top="586" left="59" width="40" height="7" font="9">Medications</text>
<text top="596" left="69" width="27" height="7" font="9">IV/Oral </text>
<text top="605" left="69" width="75" height="7" font="9">Corticosteroids, n (%)</text>
<text top="596" left="193" width="24" height="7" font="9">34 (21)</text>
<text top="596" left="293" width="24" height="7" font="9">51 (46)</text>
<text top="596" left="394" width="20" height="7" font="9">9 (10)</text>
<text top="596" left="489" width="29" height="7" font="9">&lt; 0.0001</text>
<text top="616" left="69" width="42" height="7" font="9">Epinephrine/</text>
<text top="625" left="69" width="75" height="7" font="9">Norepinephrine, n (%)</text>
<text top="616" left="195" width="20" height="7" font="9">13 (8)</text>
<text top="616" left="293" width="24" height="7" font="9">16 (15)</text>
<text top="616" left="392" width="24" height="7" font="9">14 (15)</text>
<text top="616" left="497" width="14" height="7" font="9">0.14</text>
<text top="635" left="69" width="67" height="7" font="9">Beta blockers, n (%)</text>
<text top="635" left="193" width="24" height="7" font="9">57 (35)</text>
<text top="635" left="292" width="24" height="7" font="9">25 (23)</text>
<text top="635" left="392" width="24" height="7" font="9">52 (55)</text>
<text top="635" left="489" width="30" height="7" font="9">&lt; 0.0001</text>
<text top="645" left="59" width="85" height="7" font="9">APACHE III score, mean </text>
<text top="655" left="59" width="15" height="7" font="9">(SD)</text>
<text top="645" left="192" width="26" height="7" font="9">n = 158</text>
<text top="655" left="187" width="36" height="7" font="9">52.7 (21.9)</text>
<text top="645" left="292" width="26" height="7" font="9">n = 109</text>
<text top="655" left="287" width="36" height="7" font="9">67.3 (30.1)</text>
<text top="645" left="399" width="10" height="7" font="9">n/a</text>
<text top="645" left="489" width="29" height="7" font="9">&lt; 0.0001</text>
<text top="665" left="59" width="80" height="7" font="9">ICU LOS, days, median </text>
<text top="674" left="59" width="19" height="7" font="9">(IQR)</text>
<text top="665" left="182" width="46" height="7" font="9">6.4 (3.3–13.2)</text>
<text top="665" left="284" width="42" height="7" font="9">2.9 (1.3–8.7)</text>
<text top="665" left="383" width="42" height="7" font="9">2.4 (1.3–4.2)</text>
<text top="665" left="491" width="25" height="7" font="9">&lt; 0.001</text>
<text top="684" left="59" width="68" height="7" font="9">ICU mortality, n (%)</text>
<text top="684" left="197" width="16" height="7" font="9">8 (5)</text>
<text top="684" left="292" width="24" height="7" font="9">16 (15)</text>
<text top="684" left="392" width="24" height="7" font="9">15 (16)</text>
<text top="684" left="495" width="18" height="7" font="9">0.004</text>
<text top="695" left="59" width="82" height="7" font="9">Hospital mortality, n (%)</text>
<text top="695" left="195" width="20" height="7" font="9">12 (7)</text>
<text top="695" left="293" width="24" height="7" font="9">21 (19)</text>
<text top="695" left="392" width="24" height="7" font="9">25 (27)</text>
<text top="695" left="491" width="25" height="7" font="9">&lt; 0.001</text>
<text top="717" left="59" width="491" height="7" font="9">ICU, Intensive Care Unit; STICU, Surgical Trauma ICU; MICU, Medical ICU; CCU, Coronary Care Unit; APACHE, Acute Physiological and Chronic </text>
<text top="726" left="59" width="269" height="7" font="9">Health Evaluation; n/a, not available; LOS, length of stay; IQR, interquartile range</text>
</page>
</pdf2xml>
